KLHL6

KLHL6 is a BTB-Kelch family substrate adaptor for Cullin3-RING E3 ubiquitin ligase complexes that controls lymphocyte signaling homeostasis by targeting key substrates for proteasomal degradation. In B cells, KLHL6 is essential for BCR signal transduction and germinal center formation; BCR activation triggers KLHL6-dependent ubiquitination of roquin2 and the BCR subunits CD79A/CD79B, thereby tuning surface BCR levels and downstream NF-κB signaling (PMID:16166635, PMID:29695787, PMID:38630892). In T cells, KLHL6 ubiquitinates TOX to restrain terminal exhaustion and regulates the PGAM5–Drp1 axis to maintain mitochondrial fitness, with its expression suppressed by chronic TCR stimulation through PI3K–AKT/FOXO1 signaling (PMID:41535474). Cancer-associated KLHL6 mutations disrupt Cullin3 binding or alter substrate engagement, and loss of KLHL6 function contributes to activated B-cell diffuse large B-cell lymphoma pathogenesis (PMID:29695787, PMID:38630892).

1. 2005 High

   Establishing that KLHL6 is required cell-intrinsically for BCR signal transduction and germinal center B cell biology answered the foundational question of whether this uncharacterized BTB-Kelch protein has a physiological role in the immune system.

   Evidence Global and conditional knockout mice with B-cell proliferation, Ca²⁺ flux, and PLCγ2 activation assays

   PMID:16166635

   Open questions at the time

   • Molecular mechanism of how KLHL6 influences BCR signaling was unknown
   • No substrates or E3 ligase activity had been demonstrated
   • Role in non-B lymphocytes unexplored
2. 2017 Medium

   Identification of KLHL6 as a Cullin3 adaptor and its interaction with HBXIP/Lamtor5 placed KLHL6 within the CRL3 ubiquitin ligase framework and linked it to cell-cycle gene regulation during the transitional B cell checkpoint.

   Evidence Co-immunoprecipitation in BL2 cells; gene expression profiling and flow cytometry of Klhl6-deficient B cells

   PMID:28807996

   Open questions at the time

   • HBXIP interaction shown by single Co-IP without reciprocal validation
   • No direct ubiquitination substrates identified
   • Causal relationship between APC/C target gene upregulation and B cell block not established
3. 2018 High

   Demonstrating that KLHL6–Cullin3 ubiquitinates roquin2 upon BCR activation, and that cancer-associated KLHL6 mutations abolish this activity, provided the first defined substrate and a direct mechanistic link between KLHL6 loss-of-function and DLBCL pathogenesis via TNFAIP3/NF-κB deregulation.

   Evidence AP-MS, Co-IP, ubiquitination assays, Y691F mutagenesis of roquin2, xenograft models, RNA decay assays

   PMID:29695787

   Open questions at the time

   • Whether roquin2 is the primary BCR-signaling-relevant substrate was unclear
   • Structural basis of KLHL6–substrate recognition unknown
   • Extent of the KLHL6 substrate repertoire beyond roquin2 not addressed
4. 2023 Medium

   Biochemical and structural characterization revealed that full-length KLHL6 forms homomultimers stabilized by Cullin3 binding, providing an architectural basis for understanding how the CRL3-KLHL6 complex assembles.

   Evidence Recombinant protein gel filtration and negative-staining electron microscopy

   PMID:37286065

   Open questions at the time

   • No high-resolution structure was obtained
   • Functional significance of homomultimerization for ligase activity not tested
   • Single study without independent replication
5. 2024 High

   Identification of CD79A and CD79B as direct KLHL6 ubiquitination targets resolved how KLHL6 tunes surface BCR levels and explained the domain-specific consequences of cancer mutations — BTB mutants increase and Kelch mutants decrease BCR signaling.

   Evidence High-throughput interactome screens, Co-IP, flow cytometry, domain-specific mutagenesis, KLHL6 silencing

   PMID:38630892

   Open questions at the time

   • Structural basis of Kelch domain recognition of CD79A/B not determined
   • In vivo validation in mouse models not reported
   • Whether CD79A/B and roquin2 targeting are coordinated or independent events unknown
6. 2026 High

   Extending KLHL6 function to T cells, this work showed KLHL6 ubiquitinates TOX to prevent terminal exhaustion and restrains PGAM5–Drp1-mediated mitochondrial fission, while its own expression is negatively regulated by PI3K–AKT/FOXO1 upon chronic TCR stimulation, establishing KLHL6 as a therapeutic target for reinvigorating anti-tumor immunity.

   Evidence In vivo CRISPR screens, ubiquitination assays, Co-IP, mitochondrial fission assays, adoptive T cell transfer in tumor and viral models

   PMID:41535474

   Open questions at the time

   • Whether TOX and PGAM5 ubiquitination share structural determinants recognized by the Kelch domain is unknown
   • Relative contribution of TOX degradation vs. mitochondrial fitness to T cell rejuvenation not disentangled
   • Potential off-target effects of enforced KLHL6 expression on other CRL3 substrates not assessed

• A high-resolution structure of the KLHL6–Cullin3 complex bound to substrate, and a comprehensive substrate catalog across lymphocyte lineages, are needed to unify the diverse substrate specificities and inform therapeutic strategies.
• No high-resolution cryo-EM or crystal structure of KLHL6–Cullin3–substrate ternary complex
• Full substrate repertoire across B, T, and other cell types not systematically defined
• In vivo consequences of enforcing KLHL6 expression for immunotherapy not clinically evaluated